Ioannou et al., 2013 - Google Patents
Prothymosin α and a prothymosin α-derived peptide enhance TH 1-type immune responses against defined HER-2/neu epitopesIoannou et al., 2013
View HTML- Document ID
- 11041683157653867379
- Author
- Ioannou K
- Derhovanessian E
- Tsakiri E
- Samara P
- Kalbacher H
- Voelter W
- Trougakos I
- Pawelec G
- Tsitsilonis O
- Publication year
- Publication venue
- BMC immunology
External Links
Snippet
Background Active cancer immunotherapies are beginning to yield clinical benefit, especially those using peptide-pulsed dendritic cells (DCs). Different adjuvants, including Toll-like receptor (TLR) agonists, commonly co-administered to cancer patients as part of a …
- 101700025368 ERBB2 0 title abstract description 59
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ioannou et al. | Prothymosin α and a prothymosin α-derived peptide enhance TH 1-type immune responses against defined HER-2/neu epitopes | |
| Rammensee et al. | A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer | |
| JP6435286B2 (en) | Cancer vaccine composition | |
| Duewell et al. | ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells | |
| Izumoto et al. | Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme | |
| Schaed et al. | T-cell responses against tyrosinase 368–376 (370D) peptide in HLA∗ A0201+ melanoma patients: randomized trial comparing incomplete Freund’s adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants | |
| CN104684577B (en) | Immunogenicity WT-1 peptides and its application method | |
| Baumgaertner et al. | Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope | |
| Smithers et al. | Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen | |
| ES2406077T3 (en) | P53 peptide vaccine | |
| AU2018348432A1 (en) | Microbiota sequence variants of tumor-related antigenic epitopes | |
| EP4357356A2 (en) | Antigenic peptides for prevention and treatment of b-cell malignancy | |
| EP2328923B1 (en) | Cd133 epitopes | |
| Wong et al. | Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma | |
| US7718762B2 (en) | Cancer vaccines containing epitopes of oncofetal antigen | |
| Pullarkat et al. | A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma | |
| AU2012325758A1 (en) | Antigen presenting cancer vaccine with gamma interferon | |
| US20230374455A1 (en) | T cell manufacturing compositions and methods | |
| US20170274069A1 (en) | Method for the cancer treatment and prevention of metastatic disease | |
| Kumar et al. | Autologous Hsp70 immunization induces anti-tumor immunity and increases longevity and survival of tumor-bearing mice | |
| Zhang et al. | Fucoidan from Durvillaea Antarctica enhances the anti-cancer effect of anti-PD-L1 antibody by activating dendritic cells and T cells | |
| JP2020147551A (en) | Immunopotentiator containing MHC class II restrictive epitope peptide | |
| EP1712634A1 (en) | Selection of highly efficient antigen presenting cells for regulating immunity and uses thereof | |
| van Kooyk | In-situ delivery of antigen to DC-SIGN+CD14+ dermal dendritic cells results in enhanced CD8+ T cell responses | |
| Bosch et al. | Lung cancer patients' CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of... |